Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Financing › Details

Acacia Pharma–Lundbeck: investment, 201103 financing round Series A totalling $10m incl new investor Lundbeckfond Ventures


Period Period 2011-03-31
  Successor Acacia Pharma–SEVERAL: investment, 201309 financing round Series B £15m led by new invesors Fidelity Biosciences + Novo A/S
Organisations Money taker Acacia Pharma Ltd.
  Group Acacia Pharma (Group)
  Money source Lundbeckfond Ventures
  Group Lundbeck (Group)
Products Product Baremsis (APD421)
  Product 2 venture capital
Index term Index term Acacia Pharma–SEVERAL: investment, 201103 financing round Series A $10m from new investor Lundbeckfond Ventures + existing investor Gilde Healthcare
Person Person Kördel, Johan (Lundbeck 201411 Senior Partner at Lundbeckfond Ventures)

Acacia Pharma Ltd.. (3/31/11). "Press Release: Acacia Pharma Closes $10 Million Investment Round". Cambridge.

Funds to be used to complete two Phase II programmes

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has successfully closed a funding round, raising a total of $10 million. New investor Lundbeckfond Ventures joins Gilde Healthcare in this Series A financing.

Acacia Pharma will use the proceeds to complete Phase II development of its two lead product opportunities, APD421 for the prevention of nausea & vomiting in post-surgical patients and APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients. As a consequence of the investment, Associate Professor Johan Kördel of Lundbeckfond Ventures will join the Board of Acacia Pharma.

Julian Gilbert, Acacia Pharma’s CEO said, “I am delighted to welcome Lundbeckfond Ventures to the company and thank Gilde Healthcare for their continued support. These new funds allow the company to drive its lead programmes forward to achieve significant clinical milestones as efficiently as possible.”

Johan Kördel of Lundbeckfond Ventures added, “Acacia Pharma has an experienced team and an innovative and resource efficient approach to developing several products meeting unmet medical needs in the underserved cancer supportive care area. Acacia Pharma fits well with our investment strategy.”

Pieter van der Meer of Gilde Healthcare commented, “We are pleased to offer continued support to Acacia Pharma. The company has developed a broad pipeline of product opportunities, all of which being tested in the clinic. We anticipate a bright future for the company and its shareholders.”

Record changed: 2018-02-21


Picture [iito] – Putting Information into Context 650x65px

More documents for Acacia Pharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top